Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Free Cash Flow (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Free Cash Flow data on record, last reported at -$5.1 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 40.15% year-over-year to -$5.1 million; the TTM value through Sep 2025 reached -$27.8 million, up 29.35%, while the annual FY2024 figure was -$35.8 million, 30.22% up from the prior year.
  • Free Cash Flow reached -$5.1 million in Q3 2025 per RANI's latest filing, up from -$5.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.1 million in Q1 2021 and bottomed at -$14.5 million in Q3 2023.
  • Average Free Cash Flow over 5 years is -$9.8 million, with a median of -$9.5 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: crashed 1040.92% in 2021, then skyrocketed 41.2% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$11.3 million in 2021, then decreased by 22.86% to -$13.9 million in 2022, then increased by 11.87% to -$12.2 million in 2023, then grew by 29.07% to -$8.7 million in 2024, then soared by 41.19% to -$5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$5.1 million in Q3 2025, -$5.8 million in Q2 2025, and -$8.1 million in Q1 2025.